BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

Prelude Therapeutics Incorporated – Material Contracts

NASDAQ: PRLD    
Share price (11/13/26): $3.45    
Market cap (11/13/26): $275 million

Material Contracts Filter

EX-10.2
from 10-Q 14 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 12 pages Executive Employment Agreement
12/34/56
EX-10.15
from 10-K 12 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.14
from 10-K 18 pages Registration Rights Agreement
12/34/56
EX-10.13
from 10-K 87 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.7
from 10-K 13 pages Amended Executive Employment Agreement
12/34/56
EX-10.2
from 8-K 10 pages Separation Agreement and General Release
12/34/56
EX-10.1
from 8-K 11 pages Prelude Therapeutics Incorporated Consulting Agreement
12/34/56
EX-10.13
from 10-K 24 pages Securities Purchase Agreement
12/34/56
EX-10.7
from 10-K 13 pages Executive Employment Agreement This Executive Employment Agreement (The “Agreement”), Made Between Prelude Therapeutics Incorporated, a Delaware Corporation (The “Company”), and Bryant Lim (“Executive” And, Collectively With the Company, the “Parties”), Is Entered Into as of January 30, 2023. Whereas, the Company Desires to Employ Executive as the Company’s Chief Legal Counsel and Corporate Secretary. Now, Therefore, in Consideration of the Mutual Promises and Covenants Contained Herein and for Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Is Hereby Acknowledged, the Parties Hereto Agree as Follows: 1. Employment by the Company. 1.1 Employment. This Agreement Shall Govern the Terms of Executive’s Employment With the Company, Which Shall Commence as of February 27, 2023 or Such Other Date as Mutually Determined by Executive and the Company (Such Date, the “Start Date”). 1.2
12/34/56
EX-10.1
from 10-Q 35 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicy Disclosed. Second Amendment to Single-Tenant Triple Net Lease
12/34/56
EX-10.1
from 10-Q 9 pages Prelude Therapeutics Incorporated Consulting Agreement
12/34/56
EX-10.1
from 10-Q 13 pages Executive Employment Agreement
12/34/56
EX-10.12
from 10-K 2 pages First Amendment to Single-Tenant Triple Net Lease
12/34/56
EX-10.11
from 10-K 108 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicy Disclosed. Single-Tenant Triple Net Lease
12/34/56
EX-10.10
from 10-K 12 pages Executive Employment Agreement
12/34/56
EX-10.9
from 10-K 12 pages Executive Employment Agreement
12/34/56
EX-10.8
from 10-K 12 pages Executive Employment Agreement
12/34/56
EX-10.7
from 10-K 12 pages Executive Employment Agreement
12/34/56
EX-10.8
from S-1 22 pages Executive Employment Agreement
12/34/56